Le Lézard
Classified in: Health
Subject: FDA

FDA ACCEPTS & CLOSES EMPIRICAL SPINE'S LIMIFLEXtm PMA MODULE II AS A MOTION-PRESERVING ALTERNATIVE TO LUMBAR FUSION


SAN CARLOS, Calif., July 13, 2022 /PRNewswire/ -- Empirical Spine, Inc., a medical device company creating a new class of spinal implant that works in parallel with the natural structures of the spine to restore functionality and optimize quality of life, recently had its Premarket Approval (PMA) Module II accepted and closed by the US Food & Drug Administration (FDA), an important milestone in the commercial approval process for its LimiFlextm Dynamic Sagittal Tethertm (DST).

The LimiFlex PMA Module III will be submitted later this summer, bringing it closer to commercial availability.

The LimiFlex DST is the first-of-its-kind surgical option for grade 1 degenerative spondylolisthesis (degen spondy) patients with spinal stenosis. Recognized with FDA's Breakthrough Device Designation, LimiFlex has the potential to offer grade 1 degen spondy patients a better solution compared to current options such as fusion.

"We believe LimiFlex is an exciting advancement in stabilization surgery that uses a completely different concept for durable motion preservation to better meet the pressing need for improved outcomes with a lower cost of care," says Richard Treadwell, President and CEO of Empirical Spine. "We are on schedule to submit PMA Module III later this summer, bringing this significant innovation one step closer to commercial availability. This should be welcome news to the hundreds of thousands of patients suffering from this debilitating condition who have been waiting for a treatment option with lower failure and complication rates."

Flexion, or forward bending, is the primary motion of the lumbar spine. Many common activities, including sitting, bending over to pick up an object and many manual tasks, put the lumbar spine into flexion. When one segment of the spine is weakened and unstable, as in degen spondy, the spine flexes unevenly, with a disproportionate amount of the motion occurring at the unstable level.  Decompression (laminectomy) surgery to relieve neurologic pain (sciatica) contributes to this degenerative spiral by further destabilizing the already unstable level. 

The LimiFlex DST is the only device designed to restore the natural flexion stability of the lumbar spine. The LimiFlex DST mimics and augments the anatomic ligaments to create natural, balanced motion across the spine without the use of invasive screws, rods, and bone grafts. After completion of the neural decompression/laminectomy, LimiFlex is implanted through the same incision to restore stability while maintaining balanced mobility of the spine.

LimiFlex is an investigational device that is calibrated to work with the natural biomechanics of the spine by simply augmenting the posterior tension band in a dynamic manner?only when needed?to help keep the facets engaged and add strength to the remaining ligaments. This unique approach focuses on restoring stability in flexion while allowing for normal segmental motion and halting progression of the spondylolisthesis.

LimiFlex is intended to be an alternative to spinal fusion, which has persistent and well-documented drawbacks, including being highly invasive and expensive and carrying a high risk of surgery-related complications and re-operations. Currently, an estimated 140,000 patients, of which a disproportionate percent are women over age 65, receive lumbar fusion annually for degen spondy in the US alone. Despite reported results superior to standalone decompression, instrumented fusion remains an invasive surgical option not appropriate or desirable for many patients due to its longer recovery time and postoperative complications. Post-fusion rates of adjacent segment degeneration, just one important sequela that can lead to additional fusion surgery, ranging from 30-50% in the literature.

LimiFlex received the CE Mark in 2009 and has been implanted with excellent results in more than 2,000 European patients. Results to date, including this 10-year experience, show the potential for LimiFlex to provide a robust, motion-preserving, minimally invasive, outpatient solution.

"FDA acceptance and closure of the review of the PMA Manufacturing Module demonstrates the maturity and robustness of Empirical Spine's quality system, including design controls and process validations," says Louie Fielding, COO, Empirical Spine. "The LimiFlex supply chain was thoroughly validated and qualified, previously producing commercial product for the European market. With excellent suppliers and experience manufacturing more than 2,000 LimiFlex units for the European market, we are confident that we will be ready to meet the US market demand for motion-preserving, non-fusion devices when we obtain approval from the FDA."

About LimiFlex

LimiFlexTM is the first-in-class Dynamic Sagittal Tether TM (DST),  designed to maintain motion and stability after spinal decompression, without contributing to adjacent level issues, for grade 1 lumbar degenerative spondylolisthesis patients with spinal stenosis. By augmenting the posterior band, LimiFlex creates elastic resistance to flexion and maintains lordosis. For the first time, patients and surgeons will have a minimally invasive option that relieves compressive pain without compromising segmental motion. LimiFlex is compatible with current decompression techniques and can be performed in an outpatient setting, typically in less than 20 minutes. LimiFlex does not involve any screws or bone grafts, which can cause issues by eliminating the natural motion between spine segments and compromise options for other treatments if needed.

About Empirical Spine

Empirical Spine, Inc., founded in 2015, is a privately held company creating a new standard of care in spine surgery that works in parallel with the natural structures of the spine to restore functionality and optimize quality of life. The company's LimiFlextm Dynamic Sagittal Tether (DST) is the first-of-its-kind surgical option for degenerative spondylolisthesis patients that no longer forces the trade-offs in outcomes and costs that lumbar fusion creates. LimiFlex is a minimally invasive implant designed to stabilize the spine after open decompression, while preserving motion. The company is currently concluding a pivotal IDE trial in the U.S. For more information: https://www.limiflex.com/.

Caution: The LimiFlex Dynamic Sagittal Tether is an investigational device in the United States and is limited by law to investigational use.

Media Contact:
Patty Pologruto
[email protected]

SOURCE Empirical Spine


These press releases may also interest you

at 03:00
Hypertension, or high blood pressure, affects one in three Europeans over the age of 30 and more than one billion people worldwide.  Hypertension is known as the "silent killer" because many people do not know they have it and, over time, it can lead...

at 03:00
At the Summit on Clean Cooking in Africa, World Resources Institute (WRI) and the Clean Cooking Alliance (CCA) announced a strategic partnership to further embed clean cooking into a broad range of sustainable development initiatives across the two...

at 02:00
QuTEM AB (formerly Vironova BioAnalytics AB), a leading provider of transmission electron microscopy (TEM) services, proudly announces the receipt of GMP (Good Manufacturing Practice) Certificates and Manufacturing Permits for Independent Quality...

at 01:54
FIRST QUARTER (JANUARY - MARCH 2024) Oder intake SEK 238.5 M (206.6)Net sales SEK 257.2 M (230.2)Operating profit SEK 45.8 M (23.7)Profit after tax SEK 36.7 M (17.6)Earnings per share before/after dilution SEK 1.07 (0.51)Cash flow SEK 87.9 M...

at 01:00
In response to valuable feedback from our customers, Luraco Technologies is thrilled to announce the launch of an upgrade to our medical massage chair lineup. We are introducing the Luraco i9 Max Plus Series, a revolution of the i9 Max Series. The i9...

at 00:01
Celltrion USA today announced it will present the two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) in adult patients...



News published on and distributed by: